Advanced Biliary Tract Cancer(BTC) Clinical Trial
Official title:
A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer
| NCT number | NCT02425137 |
| Other study ID # | TTYTG1308 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 2 |
| First received | |
| Last updated | |
| Start date | April 2015 |
| Est. completion date | May 2017 |
| Verified date | July 2017 |
| Source | TTY Biopharm |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Primary Objective:
To evaluate disease control rate (DCR) of S-1 in combination with gemcitabine in patients
with advanced biliary tract cancer
Secondary Objectives:
- To evaluate overall response rate (ORR)
- To evaluate progression-free survival (PFS)
- To evaluate overall survival (OS)
- To assess the safety profile
| Status | Completed |
| Enrollment | 51 |
| Est. completion date | May 2017 |
| Est. primary completion date | May 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 20 Years and older |
| Eligibility |
Inclusion Criteria: - 1.histologically confirmed biliary tract carcinoma (including intrahepatic bile duct, extrahepatic bile duct, gallbladder, and ampulla of vater); - 2.metastatic or unresectable disease; - 3.no history of chemotherapy or radiotherapy for biliary tract cancer; - 4.presence of at least one measurable tumor lesion which is defined as lesions that can be accurately measured in at least 1 dimension with longest diameter (LD) =20 mm using conventional techniques or =10 mm with spiral CT and MRI; measurable lymph nodes must be =15 mm in the short axis; - 5.adequate hematopoietic function which is defined as below: 1. hemoglobin level = 9 g/dL; 2. absolute neutrophil count (ANC) = 1,500/mm3; 3. platelet count = 100,000/mm3; - 6.adequate hepatic function which is defined as below: 1. total bilirubin = 1.5 times upper limit of normal (ULN) and < 2 mg/dL, or total bilirubin < 3 mg/dL if biliary drainage was performed; 2. Alanine aminotransferase (ALT) = 3 x ULN or ALT = 5 x ULN in the presence of liver metastasis; - 7.adequate renal function: creatinine clearance rate (CCr) = 60 mL/min ((based upon 24-hour urine collection or calculated by Cockroft-Gault formula); - 8.age of 20 years or above; - 9.ECOG performance status 0-1; - 10.life expectancy of at least 12 weeks; - 11.ability to take oral medication; - 12.ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: - 1.other malignancy within the past 5 years except for adequately treated basal or squamous cell skin cancer or cervical cancer in situ; - 2.history or known presence of brain metastasis; - 3.presence of grade 2 or above ascites or pleural effusion; - 4.presence of grade 2 or above diarrhea; - 5.presence of mental disease or psychotic manifestation; - 6.active or uncontrolled infection; - 7.significant medical conditions that is contraindicated to study medication or render patient at high risk from treatment complications based on investigator's discretion; - 8.pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential. Patients with childbearing potential shall have effective contraception for both the patient and his or her partner during the study. |
| Country | Name | City | State |
|---|---|---|---|
| Taiwan | Chang Gung Memorial Hospital | Linkou | |
| Taiwan | National Cheng Kung University Hospital | Tainan | |
| Taiwan | National Taiwan University Hospital | Taipei | |
| Taiwan | Taipei Veterans General Hospital | Taipei |
| Lead Sponsor | Collaborator |
|---|---|
| TTY Biopharm | Chang Gung Memorial Hospital, National Cheng-Kung University Hospital, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan |
Taiwan,
Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, Hamamoto Y, Ishii H, Boku N, Furuse J. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cance — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Disease control rate (DCR) | Disease control is defined as having confirmed complete or partial response or stable disease | 2 years | |
| Secondary | Objective response rate (ORR) | To assess Objective response rate (ORR) | 2 years | |
| Secondary | progression-free survival (PFS) | To assess progression-free survival (PFS) | 2 years | |
| Secondary | overall survival (OS) | To assess overall survival (OS) | 2 years | |
| Secondary | safety profile (percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v4.03 grade) | The incidence and percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v4.03 grade | 2 years |